Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.

Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.

Kacarska-Fotevska I, Volckova N, Ilievska K, Donev D.

Croat Med J. 2019 Oct 31;60(5):475-478. No abstract available.

2.

Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.

Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB.

Clin J Am Soc Nephrol. 2019 Aug 16. pii: CJN.01380219. doi: 10.2215/CJN.01380219. [Epub ahead of print]

PMID:
31420350
3.

Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.

Chacón-Araya M, Rey-Rodríguez D, Rodríguez De León F, Ramos-Esquivel A, Sunning T.

J Med Econ. 2019 Aug;22(8):736-741. doi: 10.1080/13696998.2019.1600527. Epub 2019 Apr 12.

PMID:
30915883
4.

Epoetin Beta.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

5.

Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.

Fuller DS, Robinson BM, Locatelli F, Pisoni RL.

Nephron. 2018;140(1):24-30. doi: 10.1159/000490202. Epub 2018 Jun 26.

6.

Role of erythropoietin and its receptor in the development of endometriosis in rats

Günal MY, Ozansoy M, Kılıç Ü, Keskin İ, Özdemir EM, Aslan İ, Eren Z, Ersavaş C, Kılıç E.

J Turk Ger Gynecol Assoc. 2019 Feb 26;20(1):41-46. doi: 10.4274/jtgga.galenos.2018.2018.0039. Epub 2018 Jun 19.

7.
8.

Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study.

Darsonval A, Besson V, Cavalin C.

Pharmacoecon Open. 2017 Sep;1(3):223-229. doi: 10.1007/s41669-017-0016-5.

9.

Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.

Zahidova KK.

J Basic Clin Physiol Pharmacol. 2018 Jan 26;29(1):11-17. doi: 10.1515/jbcpp-2016-0102.

PMID:
29220885
10.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.

Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):907.

11.

Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.

Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M.

J Nephrol. 2018 Jun;31(3):321-332. doi: 10.1007/s40620-017-0419-5. Epub 2017 Jun 23.

PMID:
28646375
12.

Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis.

Rasche FM, Ebert T, Beckmann J, Busch V, Barinka F, Rasche WG, Lindner TH, Schneider JG, Schiekofer S.

Exp Clin Endocrinol Diabetes. 2017 Jun;125(6):384-391. doi: 10.1055/s-0042-124577. Epub 2017 Apr 13.

PMID:
28407666
13.

Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.

Peters NO, Jay N, Cridlig J, Rostoker G, Frimat L.

BMC Nephrol. 2017 Mar 20;18(1):97. doi: 10.1186/s12882-017-0513-x.

14.
15.

Postmarketing Benefit-Risk Assessment for Erythropoiesis-Stimulating Agents Using a Health Care Database.

Sugitani Y, Udagawa Y, Matsuda S, Yamada K, Miyawaki N, Konishi I.

Ther Innov Regul Sci. 2016 Nov;50(6):823-832. doi: 10.1177/2168479016656029. Epub 2016 Jul 11.

PMID:
30231737
16.
17.
18.

Methoxy polyethylene glycol-epoetin beta for the treatment of anemia associated with chronic renal failure.

Schmid H.

Expert Rev Hematol. 2016 Jan;9(1):5-20. doi: 10.1586/17474086.2016.1112734. Epub 2015 Nov 17. Review.

PMID:
26573694
19.

Impact of anemia treatment with methoxy polyethylene glycol-epoetin beta on polymorphonuclear cells apoptosis in predialysis patients with chronic kidney disease.

Bartnicki P, Majewska E, Kowalczyk M, Baj Z, Banach M, Rysz J.

Pharmacol Rep. 2015 Oct;67(5):842-5. doi: 10.1016/j.pharep.2015.01.014. Epub 2015 Feb 7.

PMID:
26398374
20.

Identification of recombinant human EPO variants in greyhound plasma and urine by ELISA, LC-MS/MS and western blotting: a comparative study.

Timms M, Steel R, Vine J.

Drug Test Anal. 2016 Feb;8(2):164-76. doi: 10.1002/dta.1835. Epub 2015 Aug 19.

PMID:
26290355

Supplemental Content

Loading ...
Support Center